Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Soc Sci Med ; 283: 114029, 2021 08.
Article in English | MEDLINE | ID: mdl-34242890

ABSTRACT

INTRODUCTION: Interpersonal support can promote positive outcomes among people living with HIV. In order to develop an acceptable psychoeducational couples-based intervention aimed at strengthening the relationship context and improving HIV outcomes before and after pregnancy, we conducted qualitative interviews with pregnant women living with HIV and their male partners. METHODS: We interviewed a convenience clinic-based sample of pregnant women living with HIV (n = 30) and male partners (n = 18) in Lusaka, Zambia. Interviews included pile sorting relationship topics in order of perceived priority. Interviews also focused on family health concerns. Interviews were audio-recorded, translated, transcribed, and thematically analyzed. Pile sorting data was analyzed using descriptive statistics. RESULTS: All female participants were living with HIV; 61% of the male partners interviewed were additionally living with HIV. The most prioritized relationship topic among both genders was communication between couples. Honesty and respect were important relationship topics but prioritized differently based on gender. Female participants considered emotional and instrumental support from male partners critical for their physical and mental health; men did not prioritize support. Intimate partner violence was discussed often by both genders. Family health priorities included good nutrition during pregnancy, preventing infant HIV infection, safe infant feeding, sexual health, and men's alcohol use. CONCLUSIONS: A major contribution of this study is a better understanding of the dyad-level factors pregnant women living with HIV and their male partners perceive to be the most important for a healthy, well-functioning relationship. This study additionally identified gaps in antenatal health education and the specific family health issues most prioritized by pregnant women living with HIV and their male partners. The findings of this study will inform the development of an acceptable couples-based intervention with greater likelihood of efficacy in strengthening the relationship context and promoting family health during and after pregnancies that are affected by HIV.


Subject(s)
HIV Infections , Intimate Partner Violence , Female , Humans , Male , Pregnancy , Pregnant Women , Sexual Partners , Social Support , Zambia
2.
BJOG ; 126(7): 926-934, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30461170

ABSTRACT

OBJECTIVE: We evaluated residual incontinence, depression, and quality of life among Malawian women who had undergone vesicovaginal fistula (VVF) repair 12 or more months previously. DESIGN: Prospective cohort study. SETTING: Fistula Care Centre in Lilongwe, Malawi. POPULATION: Women who had undergone VVF repair in Lilongwe, Malawi at least 12 months prior to enrolment. METHODS: Self-report of urinary leakage was used to evaluate for residual urinary incontinence; depression was evaluated with the Patient Health Questionnaire-9; quality of life was evaluated with the King's Health Questionnaire. MAIN OUTCOME MEASURES: Prevalence and predictors of residual incontinence, quality of life scores, and prevalence of depression and suicidal ideation. RESULTS: Fifty-six women (19.3%) reported residual urinary incontinence. In multivariable analyses, predictors of residual urinary incontinence included: pre-operative Goh type 3 [adjusted risk ratio (aRR) 2.82; 95% confidence interval (CI) 1.61-5.27) or Goh type 4 1.08-2.78), positive postoperative cough stress test (aRR = 2.42; 95% CI 1.24-4.71) and the positive 1-hour postoperative pad test (aRR = 2.20; 95% CI 1.08-4.48). Women with Goh types 3 and 4 VVF reported lower quality of life scores. Depressive symptoms were reported in 3.5% of women; all reported residual urinary incontinence. CONCLUSIONS: While the majority of women reported improved outcomes in the years following surgical VVF repair, those with residual urinary incontinence had a poorer quality of life. Services are needed to identify and treat this at-risk group. TWEETABLE ABSTRACT: Nearly one in five women reported residual urinary incontinence at follow up, 12 or months after vesicovaginal fistula repair.


Subject(s)
Depressive Disorder/etiology , Pregnancy Complications/psychology , Quality of Life , Urinary Incontinence/psychology , Vesicovaginal Fistula/surgery , Adolescent , Adult , Depressive Disorder/epidemiology , Female , Humans , Malawi/epidemiology , Middle Aged , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Pregnancy , Pregnancy Complications/epidemiology , Prevalence , Prospective Studies , Urinary Incontinence/epidemiology , Vesicovaginal Fistula/epidemiology , Vesicovaginal Fistula/psychology , Young Adult
5.
BJOG ; 118(4): 495-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21199294

ABSTRACT

OBJECTIVE: To determine the association between the antenatal CD4(+) cell count and the development of viral drug resistance following the use of peripartum nevirapine (NVP) for perinatal HIV prevention. DESIGN: Secondary analysis of data from a previously conducted randomised controlled trial. SETTING: Lusaka, Zambia. POPULATION: HIV-positive pregnant women. METHODS: We analysed the data from a clinical trial of single-dose tenofovir/emtricitabine (TDF/FTC) to reduce viral drug resistance associated with peripartum NVP. The trial population was categorised according to antenatal CD4(+) cell count (200-350, 351-500 and >500 cells/µl). MAIN OUTCOME MEASURES: The relative risk for acquiring drug resistance, determined by consensus sequencing and oligonucleotide ligation assay (OLA), was estimated using multivariable logistic regression. RESULTS: Of the 397 study participants, 119 (30%) had a CD4(+) count of 200-350 cells/µl, 135 (34%) had a CD4(+) count of 351-500 cells/µl and 143 (36%) had a CD4(+) count of >500 cells/µl. Among women receiving no intervention, the risk for drug resistance appeared to increase as the CD4(+) cell count decreased. Participants with CD4(+) cell counts of 200-350 cells/µl randomised to the study arm had the lowest risk, suggesting a higher efficacy of the intervention within this stratum. These results were consistent at 2 and 6 weeks, regardless of how drug resistance was measured. CONCLUSIONS: Women with CD4(+) cell counts of 200-350 cells/µl may be at increased risk for viral drug resistance following the use of peripartum NVP. Given the high prevalence of NVP resistance and the clear benefits of treatment, antiretroviral therapy should be initiated among pregnant women with CD4(+) cell counts of ≤350 cells/µl.


Subject(s)
Anti-HIV Agents/therapeutic use , Drug Resistance, Viral , HIV Infections/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Nevirapine/therapeutic use , Pregnancy Complications, Infectious/drug therapy , CD4 Lymphocyte Count , Female , HIV Seropositivity , Humans , Infant, Newborn , Perinatal Care , Pregnancy , Risk Factors
6.
Afr J Reprod Health ; 13(4): 25-36, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20690271

ABSTRACT

This analysis was performed to determine the prevalence of hypertension and association of MAP (mean arterial pressure) with birth outcomes among HIV-infected pregnant women not taking antiretrovirals. HIV-infected pregnant women, enrolled into the HPTN024 trial in Tanzania, Malawi and Zambia were followed up at 26-30, 36 weeks, and delivery. The prevalence of hypertension was <1% at both 20-24 weeks and 26-30 weeks and 1.7% by 36 weeks. A 5 mm Hg elevation in MAP increased the risk of stillbirth at 20-24 weeks by 29% (p = 0.001), 32% (p = 0.001) at 26-30 weeks and of low birth weight (LBW) at 36 weeks by 26% (p = 0.001). MAP was not associated with stillbirth at 36 weeks, LBW prior to 36 weeks, preterm birth, neonatal mortality or the risk of maternal to child transmission (MTCT) of HIV.


Subject(s)
HIV Infections/epidemiology , Hypertension/epidemiology , Pregnancy Complications, Cardiovascular/epidemiology , Pregnancy Complications, Infectious/epidemiology , Pregnancy Outcome/epidemiology , Adult , Africa South of the Sahara , Blood Pressure , Body Mass Index , Female , HIV Infections/complications , Humans , Hypertension/complications , Pregnancy , Pregnancy Trimester, Third , Prevalence
7.
Int J Tuberc Lung Dis ; 12(7): 773-9, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18544203

ABSTRACT

BACKGROUND: Zambia faces overlapping tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics; however, care for co-infected patients often occurs through separate, vertical programs. OBJECTIVE: To establish a program to integrate TB and HIV services in Lusaka primary care centers. METHODS: In collaboration with the Zambian Ministry of Health, TB-HIV integration activities began in December 2005 and were expanded to seven health centers by March 2007. Principal activities included developing staff capacity to manage co-infected patients, implementing HIV testing within TB departments and establishing referral systems between departments. RESULTS: Using a provider-initiated approach, 2053 TB patients were offered HIV testing. Seventy-seven per cent agreed to be tested; 69% of those tested were HIV-infected. Of these, 59% were enrolled in HIV care. The proportion of antiretroviral treatment (ART) program enrollees who were TB-HIV co-infected increased by 38% after program implementation. The median CD4 count among co-infected patients was 161 cells/microl, with 88% eligible for ART. CONCLUSION: Integration of HIV testing and referral services into urban primary care centers identified many co-infected patients and significantly increased the proportion of TB patients among people accessing HIV care. Ongoing challenges include maximizing the number of patients accepting HIV testing and overcoming barriers to enrollment into HIV care.


Subject(s)
Delivery of Health Care, Integrated , HIV Infections/drug therapy , Primary Health Care/organization & administration , Tuberculosis/drug therapy , Anti-HIV Agents/therapeutic use , Antitubercular Agents/therapeutic use , Community Health Services , Comorbidity , Delivery of Health Care , HIV Infections/diagnosis , HIV Infections/epidemiology , Humans , National Health Programs , Tuberculosis/epidemiology , Zambia
8.
AIDS Care ; 20(3): 311-7, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18351478

ABSTRACT

Timely adherence to clinical and pharmacy appointments is well correlated with favourable patient outcomes among HIV-infected individuals on antiretroviral therapy. To date, however, there is little work exploring reasons behind missed visits or evaluating programmatic strategies to recall patients. For this study we implemented community-based follow-up of late patients as part of a large-scale programme for HIV care and treatment in Lusaka, Zambia. Through a network of local home-based care organizations, we attempted home visits to recall patients using locator information provided at time of enrolment. Between May and September 2005, home-based caregivers were dispatched to trace 1,343 patients with missed appointments. Of these, 554 (41%) were untraceable because the provided address was invalid, the patient had moved or no one was at the home. Of the remaining 789, 359 (46%) were reported to have died. Only 430 (54% of those traced, 32% overall) were contacted directly and encouraged to return for care. The likelihood of patient return was higher among traced patients in crude analysis (relative risk [RR] = 2.5; 95%CI = 1.9-3.2) and in multivariable analysis controlling for baseline body mass index, sex and CD4 + count < or = 50/microL (adjusted RR = 2.3; 95%CI = 1.7-3.2). However, the process was inefficient: one late patient returned for every 18 home visits that were made. Reasons for missed visits were provided in 271 of 430 (63%) of the patients who were successfully traced. Common reasons included feeling too sick to come to the clinic, travelling away from home and being too busy. Despite the availability of free ART in Lusaka, patients face significant barriers to attending scheduled clinical visits. Cost-effective and feasible strategies are urgently needed to improve timely patient follow-up.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , Attitude to Health , Community Health Services/standards , HIV Infections/drug therapy , Treatment Refusal/statistics & numerical data , Adult , Antiretroviral Therapy, Highly Active/economics , Appointments and Schedules , CD4 Lymphocyte Count/statistics & numerical data , Female , Follow-Up Studies , HIV Infections/economics , HIV Infections/immunology , Humans , Male , Zambia
SELECTION OF CITATIONS
SEARCH DETAIL
...